Obesity
Conditions
Keywords
Metabolic phenotype, Renal function
Brief summary
Overweight and obesity are increasingly prevalent worldwide. Weight excess increases the risk of in developing the metabolic syndrome, which is composed by a set of cardiometabolic risk factors such as abdominal adiposity, dyslipidemia, high blood pressure and elevated fasting glucose levels. Obesity and the metabolic syndrome are known to be risk factors for the development of chronic kidney disease. It is not clear however, whether they can be considered independent risk factors for impaired renal function and renal damage. Whereas obesity may represent an independent risk factor for renal damage, it is not clear yet if the contemporaneous presence of obesity and metabolic alterations is associated with an additional increase in the risk. It may be important to understand the relationship between obesity, metabolic syndrome and renal health, as treatment strategies may be different for the two metabolic phenotypes of obesity, i.e., metabolically healthy obese (MHO) and metabolically unhealthy obese (MUO) patients. The primary objective of this multicentre observational prospective study is to assess the relationship between metabolic phenotype and reduced renal function (glomerular filtration rate \<90 ml/min/1.73m2 or microalbuminuria 30-300 mg/24h) in a population of 1000 patients with overweight or obesity. The secondary aim is to study the association between diet quality, consumption of ultra-processed foods and indicators of reduced renal function and renal damage.
Interventions
OTHERDiet
Pesonalized diet plan, devoloped according to Guidelines for dietary treatment of obesity, to be followed for a duration of 12 months
Sponsors
Istituto Auxologico Italiano
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Inclusion criteria
* Age between 18 and 60 years * BMI at least 25 kg/m2
Exclusion criteria
* Pregnancy or breastfeeding * Diabetes mellitus * Renal disease * Systemic autoimmune diseases with possible renal involvement * Agonistic physical activity * Heart failure * Pharmacologcal treatment with RAAS-inhibitors, sartans, thiazide diuretics, loop diuretics * Urinary tract infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Glomerular filtration rate | At baseline and after 12 months of dietary intervention programme | Change in glomerular filtration after dietary intervention of 12 months |
| Microalbuminuria | At baseline and after 12 months of dietary intervention programme | Change in microalbuminuria after dietary intervention of 12 months |
| Glycemia | At baseline and after 12 months of dietary intervention programme | Change in glycemia after dietary intervention of 12 months |
| Body mass index | At baseline and after 12 months of dietary intervention programme | Change in body mass index after dietary intervention of 12 months |
Countries
Italy
Contacts
Primary ContactAlberto Battezzati, Prof
Backup ContactLuca Grappiolo
Outcome results
None listed